CD274 and non-small cell lung carcinoma: The FDA has indicated Ventana SP263 and Dako 28-8 as complementary diagnostics for nivolumab in advanced NSCLC and durvalumab (anti-PD-L1) for advanced urothelial carcinoma [57,58].